Cethromycin HCl harnesses a well-characterized macrolide mechanism to inhibit Plasmodium protein synthesis in the apicoplast, a class-validated target required for liver-stage parasite maturation.
What differentiates Cethromycin HCl is its preferential hepatic accumulation, enabling sustained exposure at the site of liver-stage infection.
The central translational question for the CALM program is whether sustained hepatic exposure sufficient for dormant liver-stage activity can be achieved in primates and humans.
This question is directly testable through nonhuman primate studies and early clinical pharmacokinetics, providing a clear, data-driven go/no-go decision framework prior to broader clinical development.